BioSyent Inc. (TSXV:RX)

Market Cap	131.00M
Revenue (ttm)	38.28M
Net Income (ttm)	7.82M
Shares Out	11.25M
EPS (ttm)	0.67
PE Ratio	17.44
Forward PE	14.97
Dividend	0.19 (1.63%)
Ex-Dividend Date	May 30, 2025

Volume	1,351
Average Volume	2,284
Open	11.62
Previous Close	11.70
Day's Range	11.62 - 11.70
52-Week Range	9.20 - 12.13
Beta	0.44
RSI	50.41
Earnings Date	Aug 22, 2025

About BioSyent

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2024, BioSyent's revenue was 35.03 million, an increase of 10.89% compared to the previous year's 31.59 million. Earnings were 7.27 million, an increase of 12.54%.